ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden

Blood Cancer J. 2020 Oct 12;10(10):99. doi: 10.1038/s41408-020-00364-5.

Yu-Hung Wang^#^{1

2}, Chien-Chin Lin^#^{1

2

3}, Sze-Hwei Lee^{1

3

4}, Cheng-Hong Tsai², Shan-Ju Wu², Hsin-An Hou², Tai-Chung Huang², Yuan-Yeh Kuo⁴, Ming Yao², Koping Chang⁵, Chung-Wu Lin⁵, Yun-Chu Lin⁶, Fen-Ming Tien⁶, Wen-Chien Chou^{2

3}, Jih-Luh Tang^{7

8}, Hwei-Fang Tien²

¹ Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
² Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
³ Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
⁴ Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
⁵ Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
⁶ Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
⁷ Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. [email protected].
⁸ Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. [email protected].

^# Contributed equally.

No abstract available

Publication types